ArticleUrologie (Heidelberg, Germany)2026
[Belzutifan in the treatment of renal cell carcinoma].
Article in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the first approved inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α), belzutifan represents a significant advancement in the treatment of clear cell renal cell carcinoma. By directly blocking the transcription factor it interrupts the oncogenic cascade initiated by the loss of the von Hippel-Lindau (VHL) protein. The current approval includes monotherapy in the third-line setting as well as VHL-associated tumors; however, recent data from the LITESPARK studies suggest a possible expansion into second-line and adjuvant settings. The side effect profile is characterized by specific on-target effects, such as anemia and hypoxia, which require close monitoring.
Indexed as
Identifiers
42853392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.